Celldex Therapeutics Raises $300 Million to Fund Barzolvolimab Development

Celldex Therapeutics has completed a $300 million follow-on offering to support its pipeline, particularly for barzolvolimab in chronic urticaria. This funding will help the company transition from Phase 2 to commercial readiness and potentially become a real commercial franchise. However, investors should be aware that the equity story becomes tougher if barzolvolimab underperforms in Phase 3 or commercialization proves slower or more expensive than expected.